Stock analysis, price data, and AI-powered insights for Amgen (AMGN).
Amgen operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for AMGN.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). AMGN Stock Intelligence Report. [stoxpulse.com/stocks/amgn]
Disclaimer: The information on this page about Amgen (AMGN) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Amgen.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings beat by 6%
Mar 31
MILES bought 665 shares
May 19
Kullman bought 665 shares
May 19
Morgan Stanley Raises Amgen (AMGN) Price Target Fo...
16h ago
Amgen Faces Dual Turning Point With IMDYLLTRA Gain...
17h ago
StoxPulse AI results for AMGN: Pulse Score 45.5/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$191.70B
P/E Ratio
24.8
EPS
$3.34
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Jun 25
+11.6%
Sep 25
+10.3%
Dec 25
+9.6%
Mar 26
+6.1%
Beat estimates 4 of 4 quarters (100%)
Sector
Healthcare
Industry
Biotechnology
Morgan Stanley Raises Amgen (AMGN) Price Target Following a Strong Start for Uplizna
Amgen Faces Dual Turning Point With IMDYLLTRA Gain And Tavneos Risk
Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now
Drugmakers race to find a place in the next wave of obesity drugs
The next phase of the obesity drug race
Stay informed with the top movers within the dow jones index on Friday.
The Catch Hiding In Eli Lilly Stock's Growth Story
Amgen's $500 Million Tavneos Faces FDA Withdrawal Fight